DAVID MARINE PROFESSORSHIP IN MEDICINE
Established in 1985 by the estate of David N. Marine

DAVID N. MARINE, Med 1947, was a specialist in the study of pulmonary disease and tuberculosis. The chair honors both him and his father, DAVID MARINE SR. (pictured), Med 1905, a renowned biochemical scientist. Considered the father of thyroidology in America, David Marine Sr. spent his career at Case Western Reserve University in Ohio and at Montefiore Hospital in New York. His most significant contribution to medicine came from his studies of thyroid conditions, where his observations on the relationship between iodine and goiter prevention led to the widespread use of iodized salt. Dr. Marine won the prestigious Kober Medal in 1960. He died in 1978. This professorship is to be held by the director of the Division of Pulmonary and Critical Care Medicine.

 

LANDON S. KING, MD, the David Marine Professor of Medicine, is associate professor of medicine and biological chemistry. He is a graduate of Wake Forest University and Vanderbilt University School of Medicine. He completed training in internal medicine at Johns Hopkins in 1992, followed by a year as assistant chief of service on the Osler Medical Service. In 1993, Dr. King began a fellowship in pulmonary and critical care medicine at Johns Hopkins, and in 1997 he joined the faculty. In 2005, Dr. King was named director of Hopkins' Division of Pulmonary and Critical Care Medicine.

Dr. King is a physician-scientist who has made substantial contributions to our understanding of the biology of aquaporin water channels, which play a critical role in controlling water balance in different organs and cells. Dr. King has provided novel observations into the physiological role of aquaporins in humans. Recently, Dr. King’s group has pursued studies to identify determinants of resolution from acute lung injury, a prevalent clinical condition which is often fatal. Their findings provide new insights into mechanisms underlying injury resolution in the lung, and identify potential targets for much needed therapies in a syndrome for which few therapies are available at present. Dr. King’s work is funded by the National Heart, Lung and Blood Institute. He is a member of the American Thoracic Society and the American Physiological Society, and has been elected to the American Society for Clinical Investigation.